| アブストラクト | WHAT IS KNOWN AND OBJECTIVE: The adverse events of thyroid dysfunction caused by the use of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) have not been confirmed in a real-world investigation. The aim of this study was to evaluate the relationship between thyroid dysfunction and treatment using Food and Drug Administration (FDA)-approved VEGFR-TKIs. METHODS: Four data-mining algorithms were employed to detect thyroid dysfunction signals for VEGFR-TKIs, using data in the FDA Adverse Event Reporting System (FAERS) database from 68 quarters. MySQL Workbench and R were used to conduct statistical analysis. RESULTS AND DISCUSSION: We identified 32679 reports of thyroid dysfunction, of which 1567 listed VEGFR-TKIs as the primary suspected drugs. All four algorithms showed that the strength of the signals for hypothyroidism were greater than those for hyperthyroidism, for all the VEGFR-TKIs. In most cases, the median appearance time was within 100 days of initiation of VEGFR-TKIs therapy, except in the case of ponatinib. This indicated the need to actively identify and manage thyroid dysfunction during the early stages of VEGFR-TKIs treatment. WHAT IS NEW AND CONCLUSIONS: This study systematically identified the pharmacovigilance signals of thyroid dysfunction associated with the use of VEGFR-TKIs, using the FAERS database. |
|---|
| 投稿日 | 2021/6/26 |
|---|
| 投稿者 | Liao, Xiaolan; Liu, Zhihong; Song, Hongtao |
|---|
| ジャーナル名 | Journal of clinical pharmacy and therapeutics |
|---|
| 組織名 | College of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University,;Shenyang, China.;Department of Pharmacy, 900 Hospital of the Joint Logistics Team, Fuzhou, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34169545/ |
|---|
